

SUBJECT INDEX VOLUME 25

A

Abstinence, 313
 Acetylcholine, 555, S85
 Acoustic startle, 72
 ACTH, 537, 699
 Addiction, 234, 651
 Adenosine A_{2A} receptors, 505
 Adolescence, 601, S89
 Adrenergic receptors, 904
 α_2 -Adrenergic receptors, 98
 α_2 -Adrenoceptors, 845
 Affect, 277
 Aging, 258, 766
 Agmatine, 98
 Alcohol, 332, 537
 Alcohol dependence, 936
 Alcoholism, 332, 936, S45
 Allopregnanolone, 489, 576
 Allotetrahydrodeoxycorticosterone, 489
 Alpha-2 adrenoceptor agonists, 320
 Alpha-methyl-para-tyrosine, S97
 Alzheimer's disease, 84
 AMPA, 234
 Amphetamine, 55, 157, 789, 925
 Anterior cingulate, 1, 139
 Anticholinesterase, 555
 Antidepressants, 384, 737, 845, 858
 Antinociception, 98
 Antipsychotic drugs, 224, 514, 642
 Antipsychotics, 149, 410, 489, 634
 Anxiety, 585, 601, 669, 690
 Anxiolysis, 131
 Appetite, S21
 Arithmetic, S68
 Arousal, 277
 Attention, 313
 Attention deficit hyperactivity disorder, 624, 651
 Auditory, 498
 Autonomic responses, 537
 Autoradiography, 624

B

Behavioural phenotype, 527
 Benzodiazepines, 585, 744
 Biochemical marker, 84
 Biological rhythms, S21
 Bipolar disorder, 608, 713, 729
 Body weight, 55
 Brain, 555
 Brain mapping, 925
 Brain repair, 816
 Brain stimulation reward, 234
 Brain-derived neurotrophic factor, 258
 Buprenorphine, 104
 Bupropion SR, 131
 Bupropion, 440

C

Caesarean section, 423

cAMP, 836
 Cannabis, 757
 Carbamazepine, 729
 Catalepsy, 634
 Catecholamines, S97
 CCK2 receptor-deficient mice, 690
 CD151, 729
 Cerebral cortex, 816
 Cerebrospinal fluid, 468
 Cholecystokinin-tetrapeptide (CCK-4), 699
 CHPG, 505
 Chronobiology, S102
 Cigarette smoking, S89
 Cingulate, S79
 Circadian rhythms, 267
 Clinical trial, 402, 713
 Clonidine, 845
 Clozapine, 149, 410
 Cocaine, 28, 104, 195, 320, 332, 440
 Cocaine self-administration, 185
 Cognition, 662, 757, 936
 Cognitive, 402
 Computerized assessment, 766, 777
 Conditioned avoidance response, 634
 Conditioned place preference, 41
 Conditioned reinforcement, 440
 Conditioned stimulus, 361
 Core body and skin temperatures, S92
 Cortisol, 267, 537, 699, 793
 CREB, 836
 CRF₁ receptors, 585
 CYP2D6, 737
 Cytokines, S45

D

D₄, 624
 D₂ 'knockout', 527
 D₂ receptor, 634
 D₂ receptors, 498
 d-Amphetamine, 548
 D₁-dopamine receptor, 224
 Dependence, 789
 Depersonalization, 793
 Depletion studies, S97
 Depression, 55, 267, 384, 395, 836, 871, S21, S74, S79, S89, S102
 Depressive disorders, 737, S40, S97
 Dexamethasone, 793
 Diagnosis, 373
 Differential display, S28
 Discriminative stimulus, 361
 Dissociation, 793
 Divided attention, S68
 Dominance-subordination, 277
 Dopamine, 1, 28, 149, 157, 204, 213, 234, 361, 384, 440, 468, 624, 634, 642, 679, 704, 789, S97
 Dopamine D₂ receptors, 213, 505, 527
 Dopamine D-2 receptors, 476
 Dopamine receptors, 423, 904, 514
 Dopamine reuptake inhibitor, 104
 Dopaminergic, 139
 Dorsal hippocampus, 662

Dorsal raphe nucleus, 858, 892
 Double-blind, 548
 Drug abuse, 195, 332
 Drug addiction, 341
 Drug liking, 548
 Drug model, 455
 Drug self-administration, 104, 320
 Drug withdrawal, 55
 Drug-seeking, 341
 Duloxetine, 871
 Dysphoria, 642

E

EEG sleep, S85
 EEG spectral analysis, 576
 EEG topography, S57
 Efficacy, 713
 Electroencephalography (EEG), 332, 498
 Electrophysiology, 858
 Emission computed, S74
 Encoding, 744
 Energy metabolism, S5
 Episodic memory, 744
 Estradiol, 242
 Estrogen, 881
 Ethogram, 527
 Extinction, 185, 320
 Extrapyramidal side effects, 514

F

Facial affect, 915
 Fatty acids, S36
 FDG, S74
 Fenfluramine challenge, 395
¹⁸F-Fallypride, 476
 Fgf stem cell, 805
 Fibroblast growth factor, 805
 Fluoxetine, 55, 440, 836
 fMRI, 925, S85
 FMRI, S68
 Fos, 224
 Frontal cortex, 332, 384, 662
 Functional brain imaging, S50
 Functional imaging, 165
 Functional MRI, 915, S79

G

GABA, 489, 699, 704
 GABA_A receptor, 576
 GBR-12909, 28
 Gender, 258, S89
 Gene expression, 185
 Genetics, 608
 Geriatric psychiatry, 737
 Globus pallidus, 28
 Glucocorticoids, 881
 Glucose metabolism, S50
 Glutamate, 157, 173, 234, 242, 455, 662, 704, 936

Glutamate receptors, 341
 Gonadal hormones, 118
 Grade of membership classification, 373
 Guanfacine, 402

H

Habituation, 72
 Hallucinogen, 565
 Haloperidol, 498
 Heart rate, 537, 592
 Heat loss, S92
 Heat shock protein, 258
 Heroin, 104, 320, 332
 Hippocampus, 1
 Homeobox, 805
 Hormone pulsatility, 267
 Hormones, 537
 HPA axis, 267, 793, 881
 HPA system, 699
 5-HT, S40
 5-HT_{1B}, 410
 5-HT_{1D}, 410
 5-HT_{1A} antagonist, 55
 5-HT receptors, 679, 871
 5-HT_{1A} receptors, 585, 845
 5-HT_{1B} receptors, 845
 5-HT₂ receptors, 565
 5-HT_{2C} receptors, 585
 5-HT₆ receptors, 662
 5-HT_{1A} receptor, S40
 5HT_{1D} β receptor, 608
 Human, 555, 757
 Human subjects, 548
 6-Hydroxydopamine, 204, 624
 5-Hydroxytryptamine (serotonin), 858
 Hypericum perforatum, 858
 Hypnotics, S36
 Hypocretin, S5, S14
 Hypothalamus, S21
 Hypoxia, 423

I

Iloperidone, 904
 Immunity, S45
 In situ hybridization, 173, 892
 In vivo binding, 213
 Indatraline, 104
 Interindividual variability, S57
 Intoxication, 936
 Intracranial self-stimulation, 55
 Inverse agonist, 410
 Ipsapirone, S40

K

Ketamine, 72, 165, 455, 936
 Kraepelin, 373

L

Lateral hypothalamus, 234
 Lethality, 41
 LI 160, 858
 Light and sleep, S102
 Linkage, 608
 Lithium, 729
 Locomotion, 41, 118
 Locomotor activity, 440
 Locus coeruleus, 845
 LSD, 565
 L-type calcium channel, 936

M

Magnetoencephalography (MEG), 498
 Major depression, S45
 Major depressive disorder, 131, 713
 Mania, 373
 Marijuana, 757
 MDMA, 195
 Medial prefrontal cortex, 204
 Melanotransferrin, 84
 Melatonin, S92
 Memory, 690, 936
 Metabotropic glutamate (mGlu) receptors, 173, 505
 α -Methyl-para-tyrosine, 213
 Mice, 98
 Microarray, S28
 MicroCog, 757
 Microdialysis, 149, 662, 704
 Mirror system, 915
 Mixed states, 373
 Monoamine oxidase inhibitor (MAOI), S63
 Mood regulation, S5
 Morphine, 98
 Motivation, 55
 Motor activity, 624, 690
 Motor task, 925
 Muscarinic blocker, 555
 Muscle rigidity, 514

N

Naltrexone, 537
 Narcolepsy, S5, S14, S21
 Neocortex, 816
 Neural, 805
 Neural precursors, 816
 Neural transplantation, 816
 Neurocognition, 766, 777
 Neurodevelopment, 423
 Neurogenesis, 816
 Neuroleptics, 1, 476
 Neuromuscular deficits, 690
 Neuropsychological testing, 766, 777
 Neurotrophic factor, 836
 Nicotine, 55, 601
 Nicotine gum, 313
 Nicotine withdrawal, 313
 Nimodipine, 936
 NMDA, 936
 NMDA antagonist, 173
 NMDA receptor antagonist, 258
 NMDA receptors, 28, 157
 NMDA-antagonist, 704
 N-Methyl-D-aspartate, 455
 N-Methyl-D-aspartate receptor, 242
 NonREM sleep, S57
 Noradrenaline, 204, S97
 Noradrenergic, 139
 Norepinephrine, 402
 Norepinephrine uptake, 871
 Nortriptyline, 737
 Nucleus accumbens, 204, 440, 662

O

Occasion setter, 361
 Occupancy, 476
 Olanzapine, 224, 468
 Oleamide, S36
 Oligonucleotide array sequence analysis, 737
 Opiate withdrawal, 204
 Opioid partial agonist, 104

Orexin, S5, S14
 Oscillation, 28
 Ovariectomy, 242
 Oxygen isotopes, 555

P

Panic attacks, 699
 Parietal lobes, S68
 Parkinson's disease, 505
 Paroxetine, 395
 Partial agonist, 789
 PD 128907, 361
 Performance, 757
 Perfusion, S79
 Perinatal, 423
 Peripheral benzodiazepine receptors, 669
 PET, 139, 476, S85
 PET scan, 555, S74
 Pharmacodynamics, 165
 Pharmacologic treatment, 395
 Pharmacological probes, S85
 Phencyclidine, 173, 704
 Photostimulation, 555
 Physical dependence, 41
 Physostigmine, 555
 Placebo-controlled, 548
 Positron emission tomography (PET), 213, 679, 744, S50
 Postmortem, 892
 PPI, 565
 Prefrontal, 1
 Prefrontal cortex, S68
 Prepulse inhibition, 72
 Pretreatment anxiety, 131
 Proenkephalin mRNA, 185
 Progesterone, 489
 Protein, 234
 Psychometrics, 766
 Psychosis, 455, 936
 Psychostimulant, 118
 Psychotic disorders, 904

R

[¹¹C]raclopride, 213
 Raloxifene, 242
 Rapid eye movement sleep, S50
 Rapid tryptophan depletion, S40
 Rat, 195, 234, 576, 634
 rCBF, 165
 Rearing, 118
 Receptor autoradiography, 892
 Receptor binding profile, 904
 Recurrence, 332
 Regeneration plasticity, 805
 Regional blood flow, 555
 Regional cerebral blood flow, 744
 Regional glucose metabolism, 139
 Reinforcement, 195
 Reinstatement, 320, 361
 Relapse, 320, 332, 361
 REM sleep, S85
 Reproductive hormones, S102
 Retrospective analysis, 131
 Retrosplenial cortex, 258
 Reward, 55
 Ritalin®, 651

S

SB-271046, 662
 SCH 39166, 361

Schizophrenia, 72, 149, 173, 402, 410, 423, 455, 642, 777, 915, 936
 5-5-Schizophrenia, 410
 Scopolamine, 555
 Seasonal affective disorder, S97
 Seasons, S97
 Second-order schedule, 341
 Selective attention, 498
 Selective serotonin reuptake inhibitors, 858
 Self-administration, 41, 341, 651
 Self-injurious behavior, 224
 Sensitization, 195, 224, 384, 548, 651
 Sensorimotor gating, 72
 Serotonin, 1, 55, 204, 277, 395, 440, 468, 679, 540, S85
 Serotonin receptors, 904
 Serotonin uptake, 871
 Sertraline, 131
 Sex differences, 601, 766, 777
 Side effects, 713
 SKF 81297, 361
 Sleep, 576, S5, S14, S21, S36, S40, S45, S50, S89
 Sleep deprivation, S28, S68, S79
 Sleep EEG, S63
 Sleep onset latency, S92
 Sleepiness, S92
 Slow wave sleep, S85
 Slow-wave activity, S63
 Social behavior, 277

Social cognition, 915
 Social isolation, 601
 Somatic signs, 55
 Spectral analysis, S57
 Speedball, 104
 Stem cells, 816
 Stereotypy, 118
 Stress, 320, 384, 669, 805, 836, 881
 Striatum, 157, 505, 662
 Stroop task, 139
 Substance abuse disorder, 651
 Substance related disorders, 332
 Substantia nigra, 514
 Subtypes, 373
 Suppression, 793
 Swim stress, 669

T

Tamoxifen, 242, 881
 Targeted gene deletion, 527
 Terguride, 789
 THC, 757
 Theta activity, S63
 Tolerance, 41, 576
 Tomography, S74
 Tone decision task, 925
 Topographical assessment, 527
 Transgenic knockout mice, 41

Transmembrane-4-superfamily protein, 729
 Transmission disequilibrium test, 608
 Treatment-resistant depression, 713
 Triazolam, 744
 Tryptophan, 277, S40
 Tyrosine, 149

U

Ultradian rhythms, 267

V

Vagus nerve stimulation, 713
 Valproate, 729
 Venlafaxine, 871
 Ventral striatum, 514
 Verbal learning, S68
 Vigabatrin, 699, 704
 Visual cortex, 555

W

Wakefulness, S63
 Wavelet, 28
 Withdrawal, 185, 789
 Women, S102
 Working memory, 313, 915